Insider Selling: AngioDynamics (NASDAQ:ANGO) CFO Sells $289,756.05 in Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Stephen Trowbridge sold 23,615 shares of the firm’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $12.27, for a total value of $289,756.05. Following the sale, the chief financial officer directly owned 280,461 shares of the company’s stock, valued at $3,441,256.47. This represents a 7.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

AngioDynamics Trading Down 2.9%

Shares of NASDAQ:ANGO traded down $0.36 on Friday, reaching $11.99. 475,817 shares of the company’s stock were exchanged, compared to its average volume of 531,842. AngioDynamics, Inc. has a twelve month low of $9.39 and a twelve month high of $16.29. The company has a market capitalization of $504.18 million, a price-to-earnings ratio of -15.37 and a beta of 0.30. The company has a fifty day moving average of $14.26 and a 200-day moving average of $12.46.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts forecast that AngioDynamics, Inc. will post -0.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming boosted its position in shares of AngioDynamics by 166.6% during the 3rd quarter. State of Wyoming now owns 14,750 shares of the medical instruments supplier’s stock valued at $227,000 after acquiring an additional 9,217 shares during the last quarter. Pinnacle Wealth Planning Services Inc. bought a new stake in AngioDynamics in the third quarter worth $40,000. Integrated Wealth Concepts LLC purchased a new stake in AngioDynamics during the second quarter valued at $38,000. Corient Private Wealth LP purchased a new stake in AngioDynamics during the second quarter valued at $134,000. Finally, Public Employees Retirement System of Ohio bought a new position in AngioDynamics during the second quarter valued at $64,000. Institutional investors own 89.43% of the company’s stock.

Analyst Ratings Changes

ANGO has been the topic of several research reports. Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. HC Wainwright reduced their target price on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of AngioDynamics in a research note on Friday, October 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.